News
ADC conjugation

    Antibody-drug conjugates or ADCs are an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. As the hottest research topice, ADC technology are intended to target and kill only the cancer cells and spare healthy cells. ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic(anticancer) payload or drug. Antibody-drug conjugates are examples of bioconjugates and immunoconjugates. A stable link between the antibody and cytotoxic (anti-cancer) agent is a crucial aspect of an ADC conjugation. A highly stable ADC linker will ensure that less of the cytotoxic payload falls off in circulation, driving an improved safety profile, and will also ensure that more of the payload arrives at the cancer cell, driving enhanced efficacy. Linkers are based on chemical motifs including disulfides, hydrazones or peptides (cleavable), or thioethers (noncleavable) and control the distribution and delivery of the cytotoxic agent to the target cell.
Biochempeg provide the most comprehensive medias for conjugation research.


ANTIBODY-DRUG CONJUGATIONS(ADCS)
Technique support: GMP standard production support, impurity control. Contact for Technical Files.

 

Catalog No. Name Structure M.W. Purity
MF001024 mPEG-SCM mPEG-SCM ≥95%
HO017017 COOH-PEG-COOH COOH-PEG-COOH ≥95%
MD002002 OH-PEG8-OH OH-PEG8-OH 370.436 ≥95%
MD005002 NH2-PEG12-OH NH2-PEG12-OH 545.667 ≥95%
MD001025 mPEG10-SPA mPEG10-SPA 645 ≥95%
MD001025 mPEG11-SPA mPEG11-SPA 685.75 ≥95%
MD001025 mPEG25-SPA mPEG25-SPA 1301 ≥95%
MD016050 COOH-PEG24-NH2.HCl COOH-PEG24-NH2.HCl 1182 ≥95%